“…From a clinical point of view, it has been widely demonstrated that the additional information provided by CGM sensors, when used in conjunction with SMBG data, improves the quality of glucose control [7,8]. From an academic point of view, the availability of CGM data stimulated, over the last 15 years, the development of several CGM-based applications, e.g., algorithms for the prediction of future glucose concentration to generate preventive hypo/hyperglycemic alerts [9,10,11,12,13], for the real-time modulation of the basal insulin administration [14,15,16], and for the detection of faults with glucose sensor–insulin pumps system [17,18,19,20,21]. Even more interesting is that CGM sensors enabled the realization of the artificial pancreas (AP), i.e., a device designed mainly for Type 1 diabetes (T1D), which is aimed at maintaining the BG concentration within the safety range by automatically injecting insulin via an insulin pump controlled by a closed-loop control algorithm [22,23,24,25].…”